Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Target Price at $23.67

Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) has earned an average rating of "Buy" from the eight ratings firms that are covering the company, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $23.67.

Several equities research analysts have recently issued reports on ACRV shares. HC Wainwright restated a "buy" rating and set a $22.00 price target on shares of Acrivon Therapeutics in a research note on Thursday, November 14th. Cantor Fitzgerald initiated coverage on Acrivon Therapeutics in a research report on Friday, January 31st. They issued an "overweight" rating for the company. KeyCorp initiated coverage on Acrivon Therapeutics in a research report on Friday, January 31st. They set an "overweight" rating on the stock. Finally, BMO Capital Markets decreased their price objective on Acrivon Therapeutics from $28.00 to $27.00 and set an "outperform" rating for the company in a report on Thursday, November 14th.

Acrivon Therapeutics Stock Up 7.3 %

NASDAQ ACRV traded up $0.37 during trading hours on Tuesday, reaching $5.44. 17,905 shares of the company were exchanged, compared to its average volume of 251,272. The stock has a market capitalization of $169.38 million, a P/E ratio of -2.01 and a beta of 0.85. Acrivon Therapeutics has a 1 year low of $4.69 and a 1 year high of $11.90. The business's 50 day simple moving average is $5.65 and its 200-day simple moving average is $6.87.

Remove Ads

Institutional Trading of Acrivon Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Acorn Capital Advisors LLC bought a new position in shares of Acrivon Therapeutics in the fourth quarter valued at approximately $2,440,000. Exome Asset Management LLC purchased a new stake in shares of Acrivon Therapeutics in the third quarter worth $817,000. State Street Corp raised its position in shares of Acrivon Therapeutics by 26.4% in the third quarter. State Street Corp now owns 225,896 shares of the company's stock worth $1,581,000 after buying an additional 47,233 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Acrivon Therapeutics by 548.3% during the third quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company's stock valued at $238,000 after buying an additional 28,748 shares during the period. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Acrivon Therapeutics by 29.7% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 102,784 shares of the company's stock worth $619,000 after buying an additional 23,535 shares in the last quarter. 71.62% of the stock is currently owned by institutional investors.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.